Navigation Links
3SBio and Isotechnika Pharma Announce Strategic Partnership to Develop and Commercialize Voclosporin in China
Date:8/24/2010

ney rejection following transplantation. "New Onset Diabetes After Transplant ("NODAT") is common and has become a major concern in transplantation of all organs. In kidney transplantation, it is shown to be associated with inferior long term graft and patient survival while increasing the cost of patient management. Voclosporin has not only demonstrated equal efficacy with improvements in safety, but is easy to use for clinicians which is a major benefit," stated Suphamai (Michael) Bunnapradist, MD, MS, FACP, FASN, Associate Professor of Medicine, UCLA Medical Center. Further details about the phase IIb trial results are available at http://www.newswire.ca/en/releases/archive/April2009/21/c3401.html

"A reduced burden of NODAT in patients on voclosporin at the proposed therapeutic dose was shown in the Phase 2b kidney transplant trial and would represent a significant benefit to patients," added Dr. Foster. "Published literature shows that mean graft survival of 11 years decreases to 8 years with NODAT."

"The worldwide calcineurin inhibitor market in 2009 was at least $3 billion with sales being generated by only two commercially available drugs, cyclosporine and tacrolimus," commented Dr. Foster. "Kidney transplantation represents approximately 60% of all solid organ transplants of which 93% require calcineurin inhibitors as part of their immunosuppressive regimen."

Safe Harbor Statement

This press release contains statements of a forward-looking nature. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward looking statements by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. The accuracy of these statements may be impacted by a number of busin
'/>"/>

SOURCE 3SBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. 3SBio Inc. Announces Results of Annual General Meeting
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... , May 27, 2015 /CNW/ - Export Development Canada (EDC) ... financing for Montreal,s Valeant Pharmaceuticals ... multinational pharmaceutical company. The loan is ... facility that Valeant is using to fund the repayment ... a leading gastrointestinal pharmaceutical company based in the US. ...
(Date:5/26/2015)...  The National Association of Boards of Pharmacy ® ... general availability for the .pharmacy domain begins June 3, ... may apply for .pharmacy domain names. The ... NABP has approved more than 300 .pharmacy domain names ... NABP created the .pharmacy TLD to provide consumers worldwide ...
(Date:5/26/2015)... 2015  AbbVie (NYSE: ABBV ) presented ... of its investigational, all-oral, interferon (IFN)- and ribavirin ... the Annual Meeting of the Japan Society of ... 1 GIFT-I evaluated genotype 1b (GT1b) chronic ... and without cirrhosis, who were either treatment-naïve or ...
Breaking Medicine Technology:EDC provides Valeant Pharmaceuticals with USD 67.5 M to support recent Salix Pharmaceuticals acquisition 2General Availability for .Pharmacy Domain Names Begins June 3, 2015 2AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 2AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 3AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 4AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 5AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 6
... ANGELES , Aug. 5 B. Braun Medical Inc. (B. Braun) ... gain premier access to customized, evidence-based drug libraries provided by the Zynx Health ... , , , ... , , , ...
... Aug. 5 Decision Resources, one of the ... healthcare issues, finds that, in first- and second-line treatment ... nearly 70 percent of surveyed infectious disease specialists and ... use Medarex/Merck,s CDA1 and CDB1, one year after the ...
Cached Medicine Technology:B. Braun Customers Gain Premier Access to Zynx Health Device Network's Evidence-based, Customizable Drug Library Program 2B. Braun Customers Gain Premier Access to Zynx Health Device Network's Evidence-based, Customizable Drug Library Program 3B. Braun Customers Gain Premier Access to Zynx Health Device Network's Evidence-based, Customizable Drug Library Program 4B. Braun Customers Gain Premier Access to Zynx Health Device Network's Evidence-based, Customizable Drug Library Program 5B. Braun Customers Gain Premier Access to Zynx Health Device Network's Evidence-based, Customizable Drug Library Program 6In First- and Second-Line Treatment of Clostridium Difficile Infection, Nearly 70 Percent of Surveyed Infectious Disease Specialists and Internists Will Use Fidaxomicin and Nearly Half Will Use CDA1/CDB1 2In First- and Second-Line Treatment of Clostridium Difficile Infection, Nearly 70 Percent of Surveyed Infectious Disease Specialists and Internists Will Use Fidaxomicin and Nearly Half Will Use CDA1/CDB1 3
(Date:5/26/2015)... Francisco, CA (PRWEB) May 27, 2015 ... and beautiful technology for women, today announces the ... that monitors women’s stress, sleep, activity and ovulation. ... jewelry with innovative health tracking technolo- gy, particularly ... stress levels, to provide women with lifestyle data ...
(Date:5/26/2015)... BROOK, Ill. (PRWEB) May 26, 2015 ... be an early marker of specific types of Alzheimer’s ... a new study published in the journal Radiology. ... Agosta, M.D., Ph.D., co-author of the study conducted at ... Milan, Italy. “However, white matter damage has a central ...
(Date:5/26/2015)... May 27, 2015 Visiting Nurse Association of ... at the American Cancer Society’s annual Relay for Life fundraiser. ... 12:00AM at Mennen Sports Arena, 161 East Hanover Ave, Morristown, ... the track to raise money and awareness to help the ... , According to the ACS, it is estimated that more ...
(Date:5/26/2015)... 2015 Securityhunter has been ... the United States Department of Health and Human Services ... The MATOC was awarded through the General Services Administration ... the PSC, which is a fee-for-service agency. The award ... options, and is an enterprise–wide physical security and security ...
(Date:5/26/2015)... ANGELES (PRWEB) May 27, 2015 Readers ... processes may find help in author Chester Litvin ... Psychoconduction : Litvin’s Code” (published by Trafford Publishing). , ... new approach for stimulating the brain. This book will ... to reeducate their sensory brain cells . He ...
Breaking Medicine News(10 mins):Health News:Bellabeat debuts the LEAF - smart jewelry that monitors women’s health. 2Health News:Bellabeat debuts the LEAF - smart jewelry that monitors women’s health. 3Health News:RSNA: Imaging Test May Identify Biomarker of Alzheimer’s Disease 2Health News:RSNA: Imaging Test May Identify Biomarker of Alzheimer’s Disease 3Health News:North Jersey Home Care Agency Supports Relay for Life Fundraiser 2Health News:Securityhunter Has Been Awarded a Multiple Award Task Order Contract (MATOC) by the Department of Health and Human Services 2Health News:Chester Litvin’s New Book Offers ‘Tune-Up’ for Brain Cells 2Health News:Chester Litvin’s New Book Offers ‘Tune-Up’ for Brain Cells 3
... , FRIDAY, Jan. 22 (HealthDay News) -- If you,re ready to ... potty training may be between the second and third birthdays. , ... window for moving your child out of diapers. Children who were ... incontinence -- daytime wetting and bed-wetting -- between ages 4 and ...
... physical and mental benefits as people grow old , FRIDAY, ... and gunning down bad guys might not sound like things ... , But they might want to start, some experts on ... have the potential to help seniors age more gracefully, keeping ...
... Drug Administration has approved the drug fampridine-SR for the treatment ... Medical Center (URMC) have been evaluating the effects of the ... the first medication shown to enhance some neurological functions in ... the way for today,s action by the FDA. ...
... Society report outlines 21 challenges and needs for global tobacco ... and expertise needed to reduce the rising tide of tobacco ... are the target of the multinational tobacco industry. The report ... issue of CA: A Cancer Journal for Clinicians . ...
... most women, having a baby is a joyful experience. But ... by grief, anxiety and depression. Global figures suggest that between ... first time are struck by depression. For the second birth, ... Kristin Akerjordet at the University of Stavanger in Norway, surveyed ...
... 2010) -- Weill Cornell Medical College has established a ... diverse and medically underserved communities in New York City. ... and Community Engagement (CEDREC) was created through an $8 ... and Health Disparities (NCMHD), a division of the National ...
Cached Medicine News:Health News: Potty Training Best Between Ages 2 and 3 2Health News: Potty Training Best Between Ages 2 and 3 3Health News: Potty Training Best Between Ages 2 and 3 4Health News:Video Gaming Just Might Fight Aging 2Health News:Video Gaming Just Might Fight Aging 3Health News:Researchers welcome new multiple sclerosis drug 2Health News:Researchers welcome new multiple sclerosis drug 3Health News:Global tobacco report outlines 21 challenges for 21st century 2Health News:Global tobacco report outlines 21 challenges for 21st century 3Health News:Emotions should be taken seriously 2Health News:Emotions should be taken seriously 3Health News:National Center on Minority Health and Health Disparities awards $8 million to Weill Cornell 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: